Exascale Labs (XLAB) traded down -28.87 % during a 24 hours period ending at 07:07 PM Central Europe on Monday 26th. One Exascale Labs stock can currently be bought for about USD 3.37 on popular exchanges. Current supply of Exascale Labs stocks is 91.2 mn. Exascale Labs has a current market capitalization of USD 305.5 mn and approximately USD 25.4 mn worth of Exascale Labs was traded on exchanges in the last 24 hours. Since last month end, Exascale Labs has traded 29.84 % up. Simple moving average of last 200 days is at USD 8.21. The highest price of past 52 weeks was recorded at USD 11.17 on 06/03/2026. 52 weeks low was at USD 0.78 on 10/15/2026.
Summary of the latest news for Exascale Labs
Exascale Labs Holdings Inc. announced a series of developments aimed at expanding its cloud and artificial‑intelligence offerings. The company highlighted enhancements to its AI‑driven database services, including new integration capabilities with major cloud providers that facilitate broader data access and improved workflow automation. Additionally, Exascale Labs introduced updated tools for developers, featuring low‑code and no‑code options that allow for the creation of AI agents capable of handling routine business processes. The firm also announced partnerships with leading technology and healthcare organizations to explore AI applications in clinical research, emphasizing privacy and regulatory compliance. While the updates signal a push toward more sophisticated, enterprise‑grade AI solutions, Exascale Labs remains cautious about cost management and the need for measurable returns, encouraging potential users to conduct careful assessment before scaling adoption.
Here is how related stocks have performed in the past 24 hours:
Cooper-standard (CPS) traded up 0.15 % and now trades at USD 20.44. Current market capitalisation for Cooper-standard is USD 362.3 mn. On 26 October 2026, Invex Therapeutics announced a proposed acquisition of Rekover Therapeutics, a New Zealand biotechnology company focused on repurposing nalfurafine for demyelinating diseases. The deal will be settled through the issuance of 45 million shares and performance rights that vest on specific clinical milestones. Invex plans to raise additional capital via a preliminary placement of 11.25 million shares and a subsequent placement of 113.75 million shares, all priced at $0.08 per share, to fund the acquisition and advance Rekover’s Phase 2a REVIVE study. Completion is contingent on shareholder approval, an independent expert report, and regulatory approvals, with a general meeting expected in early December 2026. The transaction is intended to expand Invex’s neurological portfolio and attract investors interested in multiple sclerosis therapeutics.
Frp (FRPH) traded down -0.94 % and now trades at USD 19.02. Frp has a market capitalisation of USD 365.9 mn. Frp has a current price to earnings ratio of 3,690.2.
Oneim Acquisition Cl (OIM) traded down -0.1 % and now trades at USD 10.1. Current market capitalisation for Oneim Acquisition Cl is USD 365.2 mn.
Gigcapital (GIX) traded down -0.1 % and now trades at USD 10.01. Gigcapital has a market capitalisation of USD 365.5 mn.
Telos (TLS) traded up 6.56 % and now trades at USD 5.12. Telos has a market capitalisation of USD 364 mn. Telstra Group Limited announced a daily buy‑back of its fully paid ordinary shares. The company confirmed it had repurchased a substantial portion of its shares in the preceding trading day, with the total number of shares bought back reflecting a notable reduction in outstanding shares. The buy‑back was conducted on the market, with the company employing a broker to execute the transactions. Telstra indicated that the buy‑back is intended to support efficient capital management, and the company retains flexibility to adjust or discontinue the program as market conditions warrant. The announcement provided details on the pricing range observed during the recent transactions, noting that the shares were acquired at prices within a specific band, and the company highlighted its capacity to maintain the program until the end of June 2027. The update underscores Telstra’s ongoing commitment to shareholder value through strategic share repurchases.
